



Södertälje, Sweden, April 6, 1999

PROPOSED MEMBERS OF THE BOARD OF ASTRA AB

As announced earlier today, the merger between Astra AB and Zeneca Group PLC has been completed. As also announced previously, the Board of AstraZeneca PLC was appointed on February 18, 1999, and will be made up as follows:

Percy Barnevik – Non-Executive Chairman
Sir David Barnes – Executive Deputy Chairman
Håkan Mogren – Executive Deputy Chairman
Tom McKillop – Chief Executive
Jonathan Symonds – Executive Director, Chief Financial Officer
Åke Stavling – Executive Director, Business Development & Integration
Claes Wilhelmsson – Executive Director, R&D
Michael Pragnell – Executive Director, Agrochemicals
Dame Bridget Ogilvie – Non-Executive Director
Sir Peter Bonfield – Non-Executive Director
Karl von der Heiden – Non-Executive Director
Erna Möller – Non-Executive Director
Lars Ramqvist – Non-Executive Director
Marcus Wallenberg – Non-Executive Director

Astra AB is now a subsidiary of AstraZeneca. The Annual General Meeting must still make decisions regarding the Board and auditors and their fees. The following proposals will be placed before today's Annual General Meeting:



Re-election of Marcus Wallenberg and election of Tom McKillop, Jonathan Symonds, Åke Stavling, Claes Wilhelmsson and Göran Lerenius as members of the Board

Election of Deloitte & Touche as auditors with Bo Magnusson, Authorized Public Accountant, as the responsible partner.

No separate remuneration is proposed for the members of the Board of Astra AB. It is proposed that remuneration be paid to auditors for work carried out as specified in a separate account.

Contact persons:

Staffan Ternby, Vice President, PR & Information, Astra AB, +46 8 553 261 07

Mikael Widell, Press Officer, PR & Information, Astra AB, +46 8 553 264 28

Michael Olsson, Manager, Investor Relations, Astra AB, +46 8 553 259 52

Jörgen Winroth, Investor Relations U.S., Astra AB, +1 609 896 4148